Is blood group associated with mortality in Crimean-Congo Hemorrhagic Fever?

Year 2011, Volume: 1 Issue: 03, 118 - 121, 01.09.2011

Fazilet Duygu Turan Kaya

https://doi.org/10.5799/ahinjs.02.2011.03.0027

Abstract

Objectives: In this trial, our purpose was to determine the distribution of blood groups in Tokat region and Crimean-Congo hemorrhagic fever (CCHF) patient group and to investigate the impact of blood groups on fatal prognosis of the disease. Material and Method: Demographic and laboratory values and blood groups of patients were recorded. In addition, distribution of blood groups among blood donors who referred to the blood center during same time interval was determined. Results: Distribution of blood groups among CCHF patients and donors in blood center were found to be similar to Turkish data (P>0.05). On the other hand, a discrepancy was determined in blood group distribution of CCHF patients with a fatal outcome, with a significantly high rate of AB Rh negative blood group in this patient group (P<0.001). Conclusion: We suggest that blood group may be associated with mortality in CCHF patients and AB Rh negative blood group may be an indicator of poor prognosis.

Keywords

Crimean-Congo hemorrhagic fever, blood groups, association

Is blood group associated with mortality in Crimean-Congo Hemorrhagic Fever?

Abstract

Keywords

-

References

• Frangoulidis D, Meyer H. Measures undertaken in the German Armed Forces Field Hospital deployed in Kosovo to contain a potential outbreak of Crimean-Congo hemorrhagic fever. Mil Med 2005; 170:366-369.
• Drosten C, Minnak D, Emmerich P, Schmitz H, Reinicke T. Crimean- Congo hemorrhagic fever in Kosovo. J Clin Micro- biol 2002;40:1122-1123.
• Andersson I, Bladh L, Mousavi-Jazi M, Magnusson KE, Lund- kvist A, Haller O, et al. Human MxA protein inhibits the rep- lication of Crimean-Congo hemorrhagic fever virus. J Virol 2004;78:4323-4329.
• Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug A, Kubar A, Akinci E. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality International Journal of Infectious Diseases 2008;12:374-379.
• Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Va- haboglu H. Crimean-Congo hemorrhagic fever outbreak in Middle Anatolia: a multicenter study of clinical features and outcome measures. J Med Microbiol 2005;54:1-5.
• Whitehouse CA. Crimean–Congo hemorrhagic fever Antiviral Research 2004;64:145–160.
• Onguru P, Dagdas S. Coagulopathy Parameters in Patients With Crimean-Congo Hemorrhagic Fever and Its Relation With Mortality. J Clin Lab Analysis 2010;24:163–166.
• Calhoun L, Petz LD. Erythrocyte antigens and antibodies. In: Williams Hematology. Beutler E, Lichtman MA, Coller BS, Kipps TJ and Seligsohn U. (eds) sixth edition, McGraw-Hill, New York 2001;1843-1858.
• Anstee DJ. The relationship between blood groups and dis- ease. Blood 2010;115:4635-4643.
• Eurosurveillance editorial office. Increase in cases of Crime- an-Congo haemorrhagic fever, Turkey, 2006. Euro Surveill 2006;11:3003.
• Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004;39:284-287.
• Ergonul O. Treatment of Crimean-Congo hemorrhagic fever.. Antiviral Research 2008;78:125–131.
• Ergun H, Ciftci E. Crimean-Congo Hemorrhagic Fever Tur- kiye Klinikleri J Pediatr Sci 2007; 3:23-26.
• Akbay T, Demiroz P, Guney C, Sengul, A, Kocabalkan, F. Blood Groups distribution due to the geographical regions in Turkey. GATA Bult 1989; 391-402.
• Calhoun L, Petz LD. Erythrocyte antigens and antibodies. In: Williams Hematology. Beutler E, Lichtman MA, Coller BS, Kipps TJ and Seligsohn U. (eds) sixth edition, McGraw-Hill, New York 2001:1843-1858.
• Jenkins PV, O’Donnell JS. ABO blood group determines plas- ma von Willebrand factor levels: a biologic function after all? Transfusion 2006;46:1836-1844.
• Trégouët DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009;113:5298-5303.
• Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated fac- tor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001;21:731-738.
• Harris JB, Khan AI, LaRocque RC, Dorer DJ, Chowdhury F, Faruque AS, et al. Blood group, immunity, and risk of infec- tion with Vibrio cholerae in an area of endemicity. Infect Im- mun 2005;73:7422-7427.
• Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, Stoll BJ, et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol 1985; 121:791-796
• Fry AE, Griffiths MJ, Auburn S, Diakite M, Forton JT, Green A, et al. Common variation in the ABO glycosyltransferase is associated with susceptibility to severe Plasmodium falci- parum malaria. Hum Mol Genet 2008;17:567-576.
• Rowe JA, Handel IG, Thera MA, Deans AM, Lyke KE, Koné A,, et al. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced roset- ting. Proc Natl Acad Sci USA 2007; 104):17471-17476.
• Frangoulidis D, Meyer H. Measures undertaken in the Ger- man Armed Forces Field Hospital deployed in Kosovo to contain a potential outbreak of Crimean-Congo hemorrhagic fever. Mil Med 2005; 170:366-369.